PMEF
RARE icon

Point72 Middle East FZE’s Ultragenyx Pharmaceutical RARE Stock Holding History

Point72 Middle East FZE’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,243
Closed -$258K – 1813
2023
Q3 		$258K Sell
7,243
-15,461
-68% -$613K 0.01% 966
2023
Q2 		$1.05M Buy
22,704
+20,437
+901% +$948K 0.03% 581
2023
Q1 		$90.9K Buy
2,267
+1,789
+374% +$76.8K ﹤0.01% 1150
2022
Q4 		$22.1K Buy
+478
New +$18.8K ﹤0.01% 1615

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Point72 Middle East FZE's RARE Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2023, closing a stake of 7,243 shares — an estimated $258K sold.

Point72 Middle East FZE first reported a position in RARE in Q4 2022 and held it in 4 quarters. The position peaked at $1.05M in Q2 2023. 236 funds tracked by Wall St. Rank hold RARE as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Ultragenyx Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 7,243 Ultragenyx Pharmaceutical shares in Q4 2023, an estimated $258K.
  • Point72 Middle East FZE first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Ultragenyx Pharmaceutical position peaked at $1.05M in Q2 2023.
  • 236 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.